117 related articles for article (PubMed ID: 19745067)
1. Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study.
Jacobsohn DA; Gilman AL; Rademaker A; Browning B; Grimley M; Lehmann L; Nemecek ER; Thormann K; Schultz KR; Vogelsang GB
Blood; 2009 Nov; 114(20):4354-60. PubMed ID: 19745067
[TBL] [Abstract][Full Text] [Related]
2. Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease.
Alam N; Atenafu EG; Tse G; Viswabandya A; Gupta V; Kim D; Lipton JH; Messner HA; Kuruvilla J
Clin Transplant; 2013; 27(6):930-7. PubMed ID: 24304375
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease.
Jacobsohn DA; Chen AR; Zahurak M; Piantadosi S; Anders V; Bolaños-Meade J; Higman M; Margolis J; Kaup M; Vogelsang GB
J Clin Oncol; 2007 Sep; 25(27):4255-61. PubMed ID: 17878478
[TBL] [Abstract][Full Text] [Related]
4. Pentostatin in steroid-refractory acute graft-versus-host disease.
Bolaños-Meade J; Jacobsohn DA; Margolis J; Ogden A; Wientjes MG; Byrd JC; Lucas DM; Anders V; Phelps M; Grever MR; Vogelsang GB
J Clin Oncol; 2005 Apr; 23(12):2661-8. PubMed ID: 15837980
[TBL] [Abstract][Full Text] [Related]
5. Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit.
Ragon BK; Mehta RS; Gulbis AM; Saliba RM; Chen J; Rondon G; Popat UR; Nieto Y; Oran B; Olson AL; Patel K; Hosing CM; Qazilbash MH; Shah N; Kebriaei P; Shpall EJ; Champlin RE; Alousi AM
Bone Marrow Transplant; 2018 Mar; 53(3):315-325. PubMed ID: 29269797
[TBL] [Abstract][Full Text] [Related]
6. Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease.
Pidala J; Kim J; Roman-Diaz J; Shapiro J; Nishihori T; Bookout R; Anasetti C; Kharfan-Dabaja MA
Ann Transplant; 2010; 15(4):21-9. PubMed ID: 21183872
[TBL] [Abstract][Full Text] [Related]
7. Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis.
Schmitt T; Luft T; Hegenbart U; Tran TH; Ho AD; Dreger P
Bone Marrow Transplant; 2011 Apr; 46(4):580-5. PubMed ID: 20562925
[TBL] [Abstract][Full Text] [Related]
8. An old drug for a new disease: pentostatin (Nipent) in acute graft-versus-host disease.
Margolis J; Vogelsang G
Semin Oncol; 2000 Apr; 27(2 Suppl 5):72-7. PubMed ID: 10877057
[TBL] [Abstract][Full Text] [Related]
9. Pentostatin for the treatment of chronic graft-versus-host disease in children.
Goldberg JD; Jacobsohn DA; Margolis J; Chen AR; Anders V; Phelps M; Vogelsang GB
J Pediatr Hematol Oncol; 2003 Jul; 25(7):584-8. PubMed ID: 12847332
[TBL] [Abstract][Full Text] [Related]
10. Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease.
Poi MJ; Hofmeister CC; Johnston JS; Edwards RB; Jansak BS; Lucas DM; Farag SS; Dalton JT; Devine SM; Grever MR; Phelps MA
Clin Pharmacokinet; 2013 Aug; 52(8):705-12. PubMed ID: 23588536
[TBL] [Abstract][Full Text] [Related]
11. Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial.
Bolaños-Meade J; Cooke KR; Gamper CJ; Ali SA; Ambinder RF; Borrello IM; Fuchs EJ; Gladstone DE; Gocke CB; Huff CA; Luznik L; Swinnen LJ; Symons HJ; Terezakis SA; Wagner-Johnston N; Jones RJ; Brodsky RA
Lancet Haematol; 2019 Apr; 6(4):e183-e193. PubMed ID: 30878319
[TBL] [Abstract][Full Text] [Related]
12. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
[TBL] [Abstract][Full Text] [Related]
13. Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial.
Pidala J; Hamadani M; Dawson P; Martens M; Alousi AM; Jagasia M; Efebera YA; Chhabra S; Pusic I; Holtan SG; Ferrara JLM; Levine JE; Mielcarek M; Anasetti C; Antin JH; Bolaños-Meade J; Howard A; Logan BR; Leifer ES; Pritchard TS; Horowitz MM; MacMillan ML
Blood; 2020 Jan; 135(2):97-107. PubMed ID: 31738834
[TBL] [Abstract][Full Text] [Related]
14. Daclizumab for children with corticosteroid refractory graft-versus-host disease.
Teachey DT; Bickert B; Bunin N
Bone Marrow Transplant; 2006 Jan; 37(1):95-9. PubMed ID: 16247417
[TBL] [Abstract][Full Text] [Related]
15. Long term outcome of patients with steroid-refractory acute intestinal graft versus host disease after treatment with pentostatin.
Klein SA; Bug G; Mousset S; Hofmann WK; Hoelzer D; Martin H
Br J Haematol; 2011 Jul; 154(1):143-6. PubMed ID: 21477160
[No Abstract] [Full Text] [Related]
16. Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation.
Kim SS
Ann Pharmacother; 2007 Sep; 41(9):1436-44. PubMed ID: 17684033
[TBL] [Abstract][Full Text] [Related]
17. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant.
Kim JG; Sohn SK; Kim DH; Lee NY; Suh JS; Lee KS; Lee KB
Eur J Haematol; 2004 Jul; 73(1):56-61. PubMed ID: 15182339
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil administered every 8 hours in combination with tacrolimus is efficacious in the prophylaxis of acute graft versus host disease in childhood, adolescent, and young adult allogeneic stem cell transplantation recipients.
Militano O; Ozkaynak MF; Mehta B; van deVen C; Hamby C; Cairo MS
Pediatr Blood Cancer; 2018 Aug; 65(8):e27091. PubMed ID: 29667720
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease.
Krejci M; Doubek M; Buchler T; Brychtova Y; Vorlicek J; Mayer J
Ann Hematol; 2005 Oct; 84(10):681-5. PubMed ID: 16001244
[TBL] [Abstract][Full Text] [Related]
20. Skin response using NIH consensus criteria vs Hopkins scale in a phase II study for steroid-refractory chronic GVHD.
Jacobsohn DA; Rademaker A; Kaup M; Vogelsang GB
Bone Marrow Transplant; 2009 Dec; 44(12):813-9. PubMed ID: 19430498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
